시장보고서
상품코드
1469138

공포증 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 공포증 유형별, 치료별, 최종사용자별, 지역별, 경쟁별(2019-2029년)

Phobia Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, By Type of Phobia, By Treatment, By End User, By Region, By Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 183 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 공포증 치료 시장은 2023년에 18억 9,000만 달러로 평가되며, 2029년까지의 CAGR은 5.53%로, 예측 기간 중 견고한 성장이 예측됩니다.

세계의 공포증 치료 시장은 최근 수년간 정신건강에 대한 인식 증가, 치료 옵션의 발전, 전 세계 공포증 관련 질환의 유병률 증가로 인해 크게 성장하고 있습니다. 공포증은 특정 대상, 상황, 활동에 대한 지속적이고 비합리적인 두려움을 특징으로 하며, 전 세계에서 수백만 명의 개인에게 영향을 미치고 삶의 질과 기능에 영향을 미치고 있습니다. 정신건강에 대한 인식이 높아짐에 따라 공포증과 관련된 문제에 대해 전문가의 도움을 구하는 사람들이 늘어나면서 효과적인 치료법에 대한 수요가 급증하고 있습니다. 이 시장에는 심리치료, 약물치료, 인지행동치료(CBT), 노출치료, 가상현실 치료와 같은 대체요법 등 다양한 치료 옵션이 포함되어 있습니다.

정신치료적 개입은 여전히 공포증 치료의 기본이며, CBT는 공포증과 관련된 부정적인 사고 패턴과 행동을 식별하고 이에 도전함으로써 점차적으로 탈감작을 촉진하고 증상을 감소시키는 가장 널리 사용되고 증거에 기반한 접근법 중 하나입니다. 또한 선택적 세로토닌 재흡수 억제제(SSRI)와 벤조디아제핀계 약물과 같은 약물 치료의 발전으로 인해 중증 공포증이나 쇠약성 공포증 환자에게 약리학적 개입이 가능해졌습니다.

가상현실(VR) 치료와 같은 혁신적인 기술의 등장은 공포증 치료에 혁명을 일으키고 있으며, 몰입형 통제된 환경을 노출 치료에 제공함으로써 개인이 안전하고 지지적인 환경에서 두려움에 맞설 수 있도록 돕고 있습니다. 세계 공포증 치료 시장은 의료비 지출 증가, 정신건강 서비스 접근성 확대, 치료 효과와 접근성 향상을 위한 연구개발 활동 증가 등의 요인에 영향을 받고 있습니다. 또한 공포증 관련 질환에 대한 인식을 높이고 정신건강에 대한 편견을 줄이기 위한 정부, 의료 기관, 비영리 단체의 구상도 시장 성장에 기여하고 있습니다. 그러나 특정 지역의 제한된 정신건강 서비스 접근성, 높은 치료 비용, 일부 치료법의 장기적 효과에 대한 우려 등이 시장 성장의 제약 요인으로 작용하고 있습니다.

주요 시장 촉진요인

정신건강 문제에 대한 인식과 수용의 증가

치료 방법의 진보

공포증 관련 장애의 유병률 증가

주요 시장이 해결해야 할 과제

정신건강 케어 서비스에 대한 액세스 제한

높은 치료비와 적정 가격에 대한 우려

주요 시장 동향

맞춤형 의료와 표적 치료

원격 요법과 디지털 헬스 솔루션

부문별 인사이트

공포증 유형별 인사이트

최종사용자별 인사이트

지역별 인사이트

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 공포증 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 공포증 유형별(동물 공포증, 고소공포증, 광장 공포증, 폐소 공포증, 사회 공포증, 기타)
    • 치료별(요법{탈감작, 플러딩, 단계적 노출, 바이오 피드백}, 약물 요법{항우울제, MAO 저해제,β차단제, 진정 최면약, 기타)
    • 최종사용자별(병원, 정신과클리닉, 공포증 치료 센터, 기타)
    • 기업별(2023년)
    • 지역별
  • 시장 맵

제6장 북미의 공포증 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 공포증 유형별
    • 치료별
    • 최종사용자별
    • 국가별
  • 북미 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제7장 유럽의 공포증 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 공포증 유형별
    • 치료별
    • 최종사용자별
    • 국가별
  • 유럽 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 공포증 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 공포증 유형별
    • 치료별
    • 최종사용자별
    • 국가별
  • 아시아태평양 국가별 분석
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주

제9장 남미의 공포증 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 공포증 유형별
    • 치료별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 공포증 치료 시장 전망

  • 시장 규모 예측
    • 금액별
  • 시장 점유율 예측
    • 공포증 유형별
    • 치료별
    • 최종사용자별
    • 국가별
  • MEA : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 이집트
    • 터키

제11장 시장 역학

  • 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 합병 매수(있는 경우)
  • 제품 출시(있는 경우)
  • 최근 동향

제13장 Porter's Five Forces 분석

  • 업계내의 경쟁
  • 신규 참여의 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Sanofi S.A.
  • Cambrex Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Midas Pharma GmbH
  • Harman Finochem Ltd
  • Pfizer Inc.
  • AstraZeneca, Plc.
  • Eli Lily and Company
  • Lupin Limited
  • GlaxoSmithKline plc

제15장 전략적 제안

제16장 면책사항

KSA 24.05.17

Global Phobia Treatment Market was valued at USD 1.89 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 5.53% through 2029. The Global Phobia Treatment Market has witnessed significant growth in recent years, driven by increasing awareness about mental health, advancements in treatment options, and a rising prevalence of phobia-related disorders worldwide. Phobias, characterized by persistent and irrational fears of specific objects, situations, or activities, affect millions of individuals globally, impacting their quality of life and functioning. As mental health awareness grows, more individuals are seeking professional help for their phobia-related concerns, leading to a surge in demand for effective treatment modalities. The market encompasses a wide range of treatment options, including psychotherapy, medication, and alternative therapies such as cognitive-behavioral therapy (CBT), exposure therapy, and virtual reality therapy.

Psychotherapeutic interventions remain the cornerstone of phobia treatment, with CBT emerging as one of the most widely utilized and evidence-based approaches. CBT helps individuals identify and challenge negative thought patterns and behaviors associated with their phobias, leading to gradual desensitization and symptom reduction. Additionally, advancements in medication options, such as selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines, offer pharmacological interventions for individuals with severe or debilitating phobia symptoms.

The advent of innovative technologies like virtual reality (VR) therapy has revolutionized phobia treatment by providing immersive, controlled environments for exposure therapy, allowing individuals to confront their fears in a safe and supportive setting. The global market for phobia treatment is also influenced by factors such as increasing healthcare expenditure, expanding access to mental health services, and growing research and development activities aimed at enhancing treatment efficacy and accessibility. Furthermore, rising initiatives by governments, healthcare organizations, and non-profit entities to raise awareness about phobia-related disorders and reduce stigma surrounding mental health contribute to market growth. However, challenges such as limited access to mental healthcare services in certain regions, high treatment costs, and concerns regarding the long-term effectiveness of some treatment modalities pose constraints to market expansion.

Key Market Drivers

Growing Awareness and Acceptance of Mental Health Issues

The growing awareness and acceptance of mental health issues have propelled significant changes in societal attitudes and approaches toward phobia treatment, consequently boosting the global phobia treatment market. As individuals become more open about their mental health struggles, there has been a parallel increase in seeking effective treatments for various phobias. One of the primary drivers behind this trend is the destigmatization of mental health discussions. With prominent figures openly discussing their experiences with anxiety disorders, phobias, and other mental health conditions, the public perception has shifted from viewing these issues as weaknesses to recognizing them as legitimate health concerns requiring attention and treatment.

Advancements in research and understanding of the underlying mechanisms of phobias have led to the development of more targeted and effective treatments. This includes cognitive-behavioral therapy (CBT), exposure therapy, medication, and emerging therapies such as virtual reality exposure therapy (VRET). As these treatment modalities gain recognition for their efficacy, more individuals are seeking professional help for their phobias.

The global phobia treatment market has responded to this increased demand by expanding its offerings and investing in innovative solutions. Pharmaceutical companies are developing new medications with fewer side effects and improved efficacy, catering to a diverse range of phobia types and severity levels. Additionally, technology-driven solutions like teletherapy platforms and mobile applications provide convenient access to therapy and support resources, further driving market growth.

Government initiatives and healthcare policies aimed at improving mental health services have contributed to the expansion of the phobia treatment market. Increased funding for mental health programs, awareness campaigns, and training for healthcare professionals have helped bridge the gap in access to quality care for individuals struggling with phobias.

Advancements in Treatment Modalities

Advancements in treatment modalities have been instrumental in propelling the global phobia treatment market forward, offering new hope and improved outcomes for individuals grappling with various phobias. These advancements encompass a wide array of innovative approaches, ranging from traditional therapies to cutting-edge technologies, all aimed at enhancing efficacy, accessibility, and patient comfort. One significant advancement is the refinement and customization of cognitive-behavioral therapy (CBT), a cornerstone in phobia treatment. Through personalized treatment plans and the integration of techniques such as exposure therapy, cognitive restructuring, and relaxation training, CBT has become more tailored to individual needs, leading to higher success rates and faster symptom relief.

The advent of virtual reality exposure therapy (VRET) has revolutionized the treatment landscape by providing immersive and controlled environments for patients to confront their fears safely. This technology allows individuals to gradually expose themselves to phobia triggers in a virtual setting, offering a realistic yet manageable way to desensitize and retrain their responses. The efficacy of VRET has been demonstrated across various phobias, including fear of flying, heights, and public speaking, making it a valuable addition to the phobia treatment toolkit.

In addition to therapeutic interventions, advancements in pharmacotherapy have expanded the options available for managing phobias. New medications with improved safety profiles and targeted mechanisms of action are being developed, offering alternatives for individuals who may not respond adequately to traditional treatments or who prefer pharmaceutical interventions.

The integration of digital health solutions has facilitated greater access to phobia treatment resources and support networks. Teletherapy platforms, mobile applications, and online support groups provide convenient avenues for individuals to connect with therapists, access self-help tools, and track their progress remotely, thereby overcoming barriers such as geographical distance and scheduling constraints.

Increasing Prevalence of Phobia-Related Disorders

The global phobia treatment market has seen a notable surge in recent years, largely attributed to the increasing prevalence of phobia-related disorders worldwide. Phobias, characterized by irrational and persistent fears of specific objects, situations, or activities, affect millions of individuals across different age groups and demographics, driving the demand for effective treatment options.

Several factors contribute to the rising prevalence of phobia-related disorders. Firstly, heightened awareness and improved diagnostic criteria have led to more accurate identification and reporting of phobias within clinical settings. With greater recognition of the impact of phobias on daily functioning and quality of life, individuals are increasingly seeking professional help to address their symptoms, thereby fueling the demand for phobia treatment services.

Changing lifestyles and environmental factors have contributed to the emergence of new phobia triggers and exacerbating existing ones. For example, advancements in technology and urbanization have introduced novel stimuli that may provoke phobic reactions, such as fear of social media scrutiny or agoraphobia related to crowded public spaces. As society evolves, so too do the array of phobia-related challenges faced by individuals, necessitating tailored and comprehensive treatment approaches.

The growing understanding of the interplay between genetics, brain chemistry, and environmental influences in the development of phobias has shed light on the complex nature of these disorders. Genetic predispositions and neurobiological factors may increase susceptibility to phobia-related conditions, underscoring the importance of early intervention and targeted treatment strategies to mitigate symptoms and prevent long-term impairment.

In response to the escalating demand for phobia treatment, the global market has witnessed significant expansion and innovation. Pharmaceutical companies are investing in the development of novel medications and therapeutic agents targeting specific phobia subtypes, while behavioral health providers are adopting evidence-based practices and integrating digital health solutions to enhance treatment outcomes and accessibility.

Key Market Challenges

Limited Access to Mental Healthcare Services

Access to mental healthcare services remains a significant challenge in many regions around the world, impeding the delivery of phobia treatment to those in need. Factors such as geographic location, socioeconomic status, and cultural barriers can create disparities in access to mental health resources, leaving many individuals without adequate support. Rural areas, in particular, often lack sufficient mental healthcare infrastructure, making it difficult for residents to access specialized treatment for phobia-related disorders. Additionally, marginalized communities may face stigma and discrimination when seeking mental health services, further exacerbating the issue of access. Addressing this challenge requires concerted efforts to improve the availability and affordability of mental healthcare services, particularly in underserved areas. Initiatives such as telemedicine and community-based outreach programs can help bridge the gap and ensure that individuals have access to timely and appropriate phobia treatment.

High Treatment Costs and Affordability Concerns

The high costs associated with phobia treatment pose a significant barrier for many patients, particularly those without adequate insurance coverage or financial resources. Psychotherapy sessions, medication, and specialized treatments such as virtual reality therapy can incur substantial expenses, making them inaccessible to individuals with limited means. Moreover, even with insurance coverage, out-of-pocket expenses and copayments can create financial strain for patients seeking ongoing treatment for phobia-related disorders. Affordability concerns may deter individuals from seeking professional help or lead to discontinuation of treatment prematurely, compromising patient outcomes. To address this challenge, stakeholders within the healthcare industry must work to reduce the financial burden of phobia treatment through measures such as price transparency, insurance reforms, and subsidies for low-income patients. Additionally, investment in cost-effective treatment modalities and preventive interventions can help mitigate long-term healthcare costs associated with untreated phobia-related disorders.

Key Market Trends

Personalized Medicine and Targeted Therapies

Personalized medicine and targeted therapies are revolutionizing the field of phobia treatment, driving growth in the global market and offering hope for individuals grappling with debilitating fears. By tailoring treatment approaches to individual characteristics and underlying mechanisms of phobia, these innovative strategies are transforming the way phobias are managed and treated.

One of the key components of personalized medicine in phobia treatment is the utilization of advanced assessment tools to identify specific phobia subtypes, severity levels, and underlying factors contributing to the condition. Through comprehensive evaluations, including clinical interviews, standardized assessments, and neuroimaging techniques, clinicians can gain a deeper understanding of each patient's unique phobia profile. This personalized approach enables them to develop targeted treatment plans that address the specific needs and challenges faced by each individual.

Advancements in genetic testing and biomarker identification are paving the way for precision medicine in phobia treatment. By identifying genetic variations and biomarkers associated with phobia susceptibility and treatment response, researchers can identify individuals who are most likely to benefit from certain therapies and medications. This targeted approach minimizes the need for trial-and-error treatments, optimizing outcomes and reducing the risk of adverse effects.

In addition to personalized assessments and targeted interventions, the development of novel therapies and treatment modalities is expanding the repertoire of options available for phobia treatment. For example, advancements in neuroscience have led to the exploration of innovative techniques such as neurostimulation and neurofeedback, which aim to modulate neural circuits implicated in phobia pathology. Similarly, the integration of virtual reality exposure therapy (VRET) and augmented reality (AR) into treatment protocols offers immersive, interactive experiences for confronting phobia triggers in a controlled environment.

Teletherapy and Digital Health Solutions

Teletherapy and digital health solutions are playing a pivotal role in transforming the landscape of phobia treatment, driving growth in the global market and offering new avenues for accessible, effective care. With advancements in technology and changing attitudes towards mental health, these innovative approaches are revolutionizing how individuals with phobias seek and receive treatment. Teletherapy, also known as telepsychology or online therapy, involves delivering therapy sessions remotely via video conferencing, phone calls, or messaging platforms. This modality eliminates geographical barriers, allowing individuals to access specialized phobia treatment regardless of their location. Moreover, teletherapy offers flexibility in scheduling, making it easier for individuals to fit treatment into their busy lives. This convenience factor encourages more people to seek help for their phobias, thereby driving demand in the global market.

Digital health solutions encompass a wide range of technologies, including mobile applications, wearable devices, and virtual reality (VR) platforms, all of which are making significant contributions to phobia treatment. Mobile apps offer self-guided interventions, such as relaxation exercises and exposure therapy tools, empowering individuals to manage their phobias independently between therapy sessions. Wearable devices, equipped with biofeedback sensors, provide real-time monitoring of physiological responses, enabling therapists to tailor interventions based on objective data. Meanwhile, VR platforms offer immersive, controlled environments for exposure therapy, allowing individuals to confront their fears safely and gradually.

The adoption of teletherapy and digital health solutions has been further accelerated by the COVID-19 pandemic, which prompted a shift towards remote healthcare delivery. With in-person appointments limited or unavailable, teletherapy emerged as a lifeline for individuals in need of mental health support, including those struggling with phobias. This increased acceptance and utilization of telehealth services have contributed to the expansion of the global phobia treatment market, as more individuals recognize the benefits of accessing care from the comfort and safety of their homes.

Segmental Insights

Type of Phobia Insights

Based on the type of phobia, social phobia segment emerged as the dominant segment in the global phobia treatment market in 2023.Social phobia is one of the most prevalent phobia-related disorders, affecting a large proportion of the population worldwide. As awareness of mental health issues continues to grow, more individuals are seeking treatment for social phobia, thereby driving demand in the market. The integration of teletherapy and digital health solutions has made treatment more accessible and convenient for individuals with social phobia. With the ability to access therapy sessions remotely and utilize self-help tools via mobile applications, patients are empowered to actively participate in their treatment, driving further growth in the market.

End User Insights

Based on the end user, psychiatry clinics segment emerged as the dominant segment in the global phobia treatment market in 2023.Psychiatry Clinics specialize in the diagnosis, treatment, and management of mental health disorders, including phobias. As dedicated facilities staffed by psychiatrists, psychologists, and other mental health professionals, these clinics offer comprehensive and specialized care tailored to the needs of individuals with phobia-related disorders. The expertise and resources available in psychiatry clinics make them well-equipped to provide evidence-based treatments, such as cognitive-behavioral therapy (CBT) and exposure therapy, which are crucial for effective phobia management.Psychiatry Clinics play a vital role in research and innovation in the field of phobia treatment. Many clinics are involved in clinical trials, research studies, and academic collaborations aimed at advancing understanding and improving treatment outcomes for phobia-related disorders.

Regional Insights

North America emerged as the dominant region in the Global Phobia Treatment Market in 2023, holding the largest market share.North America boasts advanced healthcare infrastructure and a robust mental health care system, making it well-equipped to address the needs of individuals with phobia-related disorders. The region is home to numerous renowned medical institutions, psychiatric facilities, and research centers specializing in mental health, offering state-of-the-art treatment modalities and innovative therapies for phobia management. There is a growing awareness and acceptance of mental health issues in North America, leading to increased recognition and diagnosis of phobia-related disorders. As societal stigma surrounding mental health diminishes, more individuals are seeking treatment for phobias, thereby driving demand in the market.

Key Market Players

Sanofi S.A

Cambrex Corporation

Teva Pharmaceutical Industries Ltd

Midas Pharma GmbH

Harman Finochem Ltd

Pfizer Inc.

AstraZeneca, Plc.

Eli Lily and Company

Lupin Limited

GlaxoSmithKline plc

Report Scope:

In this report, the Global Phobia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Phobia Treatment Market,By Type of Phobia:

  • Zoophobia
  • Acrophobia
  • Agoraphobia
  • Claustrophobia
  • Social Phobia
  • Others

Phobia Treatment Market,By Treatment:

  • Therapy (Desensitization, Flooding, Graded Exposures, Biofeedback)
  • Medication (Antidepressants, MAO inhibitors, Beta-Blockers, Sedative-Hypnotic Drugs, Others)

Phobia Treatment Market,End User:

  • Hospitals
  • Psychiatry Clinics
  • Phobia Treatment Centers
  • Others

Phobia Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Phobia Treatment Market.

Available Customizations:

Global Phobia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, and Trends

4.Voice of Customer

5.Global Phobia Treatment Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Type of Phobia (Zoophobia, Acrophobia, Agoraphobia, Claustrophobia, Social Phobia, Others)
    • 5.2.2.By Treatment (Therapy {Desensitization, Flooding, Graded Exposures, Biofeedback}, Medication {Antidepressants, MAO inhibitors, Beta-Blockers, Sedative-Hypnotic Drugs, Others})
    • 5.2.3.By End User (Hospitals, Psychiatry Clinics, Phobia Treatment Centers, Others)
    • 5.2.4.By Company (2023)
    • 5.2.5.By Region
  • 5.3.Market Map

6.North America Phobia Treatment Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Type of Phobia
    • 6.2.2.By Treatment
    • 6.2.3.By End User
    • 6.2.4.By Country
  • 6.3.North America: Country Analysis
    • 6.3.1.United States Phobia Treatment Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Type of Phobia
        • 6.3.1.2.2.By Treatment
        • 6.3.1.2.3.By End User
    • 6.3.2.Mexico Phobia Treatment Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Type of Phobia
        • 6.3.2.2.2.By Treatment
        • 6.3.2.2.3.By End User
    • 6.3.3.Canada Phobia Treatment Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Type of Phobia
        • 6.3.3.2.2.By Treatment
        • 6.3.3.2.3.By End User

7.Europe Phobia Treatment Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Type of Phobia
    • 7.2.2.By Treatment
    • 7.2.3.By End User
    • 7.2.4.By Country
  • 7.3.Europe: Country Analysis
    • 7.3.1.France Phobia Treatment Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Type of Phobia
        • 7.3.1.2.2.By Treatment
        • 7.3.1.2.3.By End User
    • 7.3.2.Germany Phobia Treatment Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Type of Phobia
        • 7.3.2.2.2.By Treatment
        • 7.3.2.2.3.By End User
    • 7.3.3.United Kingdom Phobia Treatment Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Type of Phobia
        • 7.3.3.2.2.By Treatment
        • 7.3.3.2.3.By End User
    • 7.3.4.Italy Phobia Treatment Market Outlook
      • 7.3.4.1.Market Size Forecast
        • 7.3.4.1.1.By Value
      • 7.3.4.2.Market Share Forecast
        • 7.3.4.2.1.By Type of Phobia
        • 7.3.4.2.2.By Treatment
        • 7.3.4.2.3.By End User
    • 7.3.5.Spain Phobia Treatment Market Outlook
      • 7.3.5.1.Market Size Forecast
        • 7.3.5.1.1.By Value
      • 7.3.5.2.Market Share Forecast
        • 7.3.5.2.1.By Type of Phobia
        • 7.3.5.2.2.By Treatment
        • 7.3.5.2.3.By End User

8.Asia-Pacific Phobia Treatment Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Type of Phobia
    • 8.2.2.By Treatment
    • 8.2.3.By End User
    • 8.2.4.By Country
  • 8.3.Asia-Pacific: Country Analysis
    • 8.3.1.China Phobia Treatment Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Type of Phobia
        • 8.3.1.2.2.By Treatment
        • 8.3.1.2.3.By End User
    • 8.3.2.India Phobia Treatment Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Type of Phobia
        • 8.3.2.2.2.By Treatment
        • 8.3.2.2.3.By End User
    • 8.3.3.South Korea Phobia Treatment Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Type of Phobia
        • 8.3.3.2.2.By Treatment
        • 8.3.3.2.3.By End User
    • 8.3.4.Japan Phobia Treatment Market Outlook
      • 8.3.4.1.Market Size Forecast
        • 8.3.4.1.1.By Value
      • 8.3.4.2.Market Share Forecast
        • 8.3.4.2.1.By Type of Phobia
        • 8.3.4.2.2.By Treatment
        • 8.3.4.2.3.By End User
    • 8.3.5.Australia Phobia Treatment Market Outlook
      • 8.3.5.1.Market Size Forecast
        • 8.3.5.1.1.By Value
      • 8.3.5.2.Market Share Forecast
        • 8.3.5.2.1.By Type of Phobia
        • 8.3.5.2.2.By Treatment
        • 8.3.5.2.3.By End User

9.South America Phobia Treatment Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Type of Phobia
    • 9.2.2.By Treatment
    • 9.2.3.By End User
    • 9.2.4.By Country
  • 9.3.South America: Country Analysis
    • 9.3.1.Brazil Phobia Treatment Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Type of Phobia
        • 9.3.1.2.2.By Treatment
        • 9.3.1.2.3.By End User
    • 9.3.2.Argentina Phobia Treatment Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Type of Phobia
        • 9.3.2.2.2.By Treatment
        • 9.3.2.2.3.By End User
    • 9.3.3.Colombia Phobia Treatment Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Type of Phobia
        • 9.3.3.2.2.By Treatment
        • 9.3.3.2.3.By End User

10.Middle East and Africa Phobia Treatment Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Type of Phobia
    • 10.2.2.By Treatment
    • 10.2.3.By End User
    • 10.2.4.By Country
  • 10.3.MEA: Country Analysis
    • 10.3.1.South Africa Phobia Treatment Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Type of Phobia
        • 10.3.1.2.2.By Treatment
        • 10.3.1.2.3.By End User
    • 10.3.2.Saudi Arabia Phobia Treatment Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Type of Phobia
        • 10.3.2.2.2.By Treatment
        • 10.3.2.2.3.By End User
    • 10.3.3.UAE Phobia Treatment Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Type of Phobia
        • 10.3.3.2.2.By Treatment
        • 10.3.3.2.3.By End User
    • 10.3.4.Egypt Phobia Treatment Market Outlook
      • 10.3.4.1.Market Size Forecast
        • 10.3.4.1.1.By Value
      • 10.3.4.2.Market Share Forecast
        • 10.3.4.2.1.By Type of Phobia
        • 10.3.4.2.2.By Treatment
        • 10.3.4.2.3.By End User
    • 10.3.5.Turkey Phobia Treatment Market Outlook
      • 10.3.5.1.Market Size Forecast
        • 10.3.5.1.1.By Value
      • 10.3.5.2.Market Share Forecast
        • 10.3.5.2.1.By Type of Phobia
        • 10.3.5.2.2.By Treatment
        • 10.3.5.2.3.By End User

11.Market Dynamics

  • 11.1.Drivers
  • 11.2.Challenges

12.Market Trends Developments

  • 12.1.Merger Acquisition (If Any)
  • 12.2.Product Launches (If Any)
  • 12.3.Recent Developments

13.Porters Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Products

14.Competitive Landscape

  • 14.1.Sanofi S.A.
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Products Services
    • 14.1.4.Financials (As Reported)
    • 14.1.5.Recent Developments
    • 14.1.6.Key Personnel Details
    • 14.1.7.SWOT Analysis
  • 14.2.Cambrex Corporation
  • 14.3.Teva Pharmaceutical Industries Ltd.
  • 14.4.Midas Pharma GmbH
  • 14.5.Harman Finochem Ltd
  • 14.6.Pfizer Inc.
  • 14.7.AstraZeneca, Plc.
  • 14.8.Eli Lily and Company
  • 14.9.Lupin Limited
  • 14.10.GlaxoSmithKline plc

15.Strategic Recommendations

16.About Us Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제